Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab
Firm Prepares To Launch First Humira Biosimilar At A ‘Pivotal Time’ For The US Market
Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.
